TOKYO & BOSTON — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. [Read more…]
Exclusive Investment Opportunity in Mexico with PRMedica Global
PRMedica Global, a distinguished British-incorporated company based in Los Cabos, Mexico, invites you to explore a premium investment opportunity in the growing field of regenerative medicine. With a specialized focus on advanced treatments using stem cells, exosomes, peptides, natural killer (NK) cells, and CAR-T cell therapies, PRMedica is at the forefront of medical innovation. Its treatments are designed to target a wide spectrum of health concerns, including orthopedic and musculoskeletal disorders, arthritis, autoimmune diseases, anti-aging solutions, neurological conditions, and more. [Read more…]
Cynata Introduces Critical Innovation into MSC Manufacturing
In the context of cell therapy, product innovation is the introduction of a cellular product that is new or has significantly improved characteristics or intended uses. Over the past decade, a great deal of attention has been given to cell therapy product innovation, as demonstrated by the thousands of cell therapy products that have now entered clinical trials worldwide.
In contrast, process innovation refers to the implementation of a new or significantly improved production or delivery method. In the context of cell therapy, process innovation has received much less attention from the marketplace. [Read more…]
Stemcyte First Biotech to Receive FDA Approval of a Cord Blood Derived Cellular Therapeutic
FDA Grants Approval to StemCyte for REGENECYTE™ Cord Blood Cell Therapy
StemCyte Inc., a subsidiary of StemCyte International Ltd., has achieved a landmark in regenerative medicine with the U.S. Food and Drug Administration’s (FDA) approval of its Biologics License Application (BLA) for REGENECYTE™. Announced on November 22, 2024, this cord blood derived cellular therapeutic is designed to treat patients with blood and immune system disorders, making StemCyte the first commercial biotech company to receive a biologics license for a cord blood stem cell therapy. [Read more…]
FREE organoid and organ-on-chip TRAINING and TICKETS at WORD+2025!
We are excited to announce these latest organoid and organ-on-a-chip partnerships for training and publishing.
WORC.Community, the founders of WORD+2025, QMUL Centre for Predictive in vitro Models and the University of Bern are excited to announce a new Organoid and Organ-on-a-chip training partnership on day three of WORD+2025. The training is a series of interactive lectures in the main auditorium. You’ll learn about the latest techniques and key methods employed at both universities. In addition, there will also be demonstrations from key technologies used in their workflows. [Read more…]
- « Previous Page
- 1
- …
- 85
- 86
- 87
- 88
- 89
- …
- 340
- Next Page »